keyword
https://read.qxmd.com/read/33153727/drug-drug-interactions-of-the-nonsteroidal-mineralocorticoid-receptor-antagonist-apararenone-with-midazolam-warfarin-and-digoxin-a-phase-1-studies-in-healthy-volunteers
#21
JOURNAL ARTICLE
Tadakatsu Nakamura, Hidetoshi Shimizu, Atsuhiro Kawaguchi
PURPOSE: To characterize the clinical relevance of in vitro drug-drug interaction findings with apararenone (MT-3995), the effects of apararenone on the sensitive substrates of cytochrome P450 3A4 (midazolam) and 2C9 (warfarin), and P-glycoprotein (digoxin), were assessed through a series of studies conducted in healthy volunteers. METHODS: Three studies were conducted in 56 healthy adults. Study 1 investigated the effects of the administration of apararenone with midazolam; apararenone was administered on days 2 (320 mg) and days 3-15 (20 mg/d), and midazolam 2 mg, on days 1 and 15...
November 2, 2020: Clinical Therapeutics
https://read.qxmd.com/read/32569249/cardiovascular-effects-of-energy-drinks-in-the-pediatric-population
#22
JOURNAL ARTICLE
Mohamad Moussa, Keith Hansz, Michaela Rasmussen, Cassidy Gillman, Casey Pollard, Eunice Kwak, Eugene Izsak
Consumption of energy drinks in the pediatric population is correlated with more emergency department visits and causes adverse reactions, such as neurological, psychiatric, gastrointestinal, renal, and cardiovascular effects. These cardiovascular complications include increased cardiometabolic risk with high intake of sugar, short-term blood pressure increases and a decrease in cerebral blood flow due to the caffeine content, increased or decreased blood pressure from taurine, unmasked cardiac conditions, such as channelopathies, and atrial and ventral fibrillations...
June 18, 2020: Pediatric Emergency Care
https://read.qxmd.com/read/32465225/impact-of-heart-failure-drug-therapy-on-gi-bleeding-rates-in-lvad-recipients-an-intermacs-analysis
#23
JOURNAL ARTICLE
D L Jennings, L Truby, J Fried, K Clerkin, J Griffin, J Raikhelkar, K Axsom, E Lin, J Haythe, M Yuzefpolskaya, P Colombo, G Sayer, M Farr, H Takayama, K Takeda, Y Naka, N Uriel, V K Topkara
PURPOSE: Gastrointestinal bleeding (GIB) remains a common and vexing complication of left ventricular assist device (LVAD) support. Recent single-center analyses suggest that ACE inhibitors (ACEi)/angiotensin receptor blockers (ARB) and digoxin may prevent GIB in LVAD patients. Here we evaluate the effect of heart failure (HF) drug therapies on rates of GIB through analysis of the INTERMACS registry database. METHODS: 13,732 patients who received a continuous-flow LVAD and were on antiplatelet therapy coupled with warfarin anticoagulation at 3 months of pump support were included in the analysis...
April 2020: Journal of Heart and Lung Transplantation
https://read.qxmd.com/read/32458378/metabolism-and-pharmacokinetic-drug-drug-interaction-profile-of-vericiguat-a-soluble-guanylate-cyclase-stimulator-results-from-preclinical-and-phase-i-healthy-volunteer-studies
#24
JOURNAL ARTICLE
Michael Boettcher, Michael Gerisch, Maximilian Lobmeyer, Nina Besche, Dirk Thomas, Mireille Gerrits, Julia Lemmen, Wolfgang Mueck, Martin Radtke, Corina Becker
BACKGROUND: Vericiguat is a stimulator of soluble guanylate cyclase currently under investigation as a first-in-class therapy for worsening chronic heart failure (NCT02861534). Patients with heart failure often require polypharmacy because of comorbidities. Hence, understanding the clearance mechanisms, elimination, and potential for pharmacokinetic drug-drug interactions of vericiguat is important for dose recommendations in this patient population. METHODS: Biotransformation and perpetrator properties of vericiguat were characterized in vitro using human hepatocytes, liver microsomes, and recombinant enzymes...
November 2020: Clinical Pharmacokinetics
https://read.qxmd.com/read/32138495/rare-interaction-of-warfarin-and-digoxin-in-a-case-of-digoxin-toxicity
#25
JOURNAL ARTICLE
Rajiv Raina, Madan Kaushik, Sanjay Mahajan, Roshan Thakur, Ritin, Satish, Vikas Banyal
Warfarin is known to interact with many drugs and can lead to serious consequences. We report a case of 52 years old female patient from Himachal Pradesh. During hospital stay patient developed coagulopathy in form of INR above 10 and bradycardia with ventricular rate on ECG with digoxin level of 3.76 ng/ml. In this way digoxin toxicity was confirmed and it was considered as cause of coagulopathy after ruling out interactions of warfarin.
March 2020: Journal of the Association of Physicians of India
https://read.qxmd.com/read/31742659/clinical-relevance-of-st-john-s-wort-drug-interactions-revisited
#26
REVIEW
Simon Nicolussi, Jürgen Drewe, Veronika Butterweck, Henriette E Meyer Zu Schwabedissen
The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti-depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago. In 2000, a pharmacokinetic interaction between SJW and cyclosporine caused acute rejection in two heart transplant patients. Since then, subsequent research has shown that SJW altered the pharmacokinetics of drugs such as digoxin, tacrolimus, indinavir, warfarin, alprazolam, simvastatin, or oral contraceptives...
March 2020: British Journal of Pharmacology
https://read.qxmd.com/read/31384400/evaluation-of-drugs-used-in-chronic-heart-failure-at-tertiary-care-centre-a-hospital-based-study
#27
JOURNAL ARTICLE
Rinku Ghimire, Sahadeb Prasad Dhungana
Introduction: There is lack of data on pattern of use of drugs in patients with chronic heart failure (CHF) from Nepalese population. This study was conducted to explore the trends of evidence based medications used for CHF in our population. Methods: This is a cross-sectional study on 200 consecutive patients with New York Heart Association (NYHA) class II to IV symptoms of CHF who attended cardiology clinic or admitted from September 2017 to August 2018 at Nobel Medical College Teaching Hospital, Biratnagar, Nepal...
2019: Journal of Cardiovascular and Thoracic Research
https://read.qxmd.com/read/31073352/interaction-between-warfarin-and-astaxanthin-a-case-report
#28
Naiyana Santiyanon, Suwimon Yeephu
This report explains the potential interaction between warfarin and astaxanthin in a 69-year-old Thai woman with history of ischemic stroke. Before taking astaxanthin, the patient used constant doses of warfarin, atenolol, digoxin, aspirin, omeprazole, and simvastatin concomitantly for 17 days without any signs and symptoms of adverse events. One day after astaxanthin was supplemented to her treatment regimen, ecchymosis was found on the right side of her groin and thigh. On the next day, area of ecchymosis was larger...
May 2019: Journal of Cardiology Cases
https://read.qxmd.com/read/30968335/assessment-of-drug-drug-interactions-between-taspoglutide-a-glucagon-like-peptide-1-agonist-and-drugs-commonly-used-in-type-2-diabetes-mellitus-results-of-five-phase-i-trials
#29
JOURNAL ARTICLE
Katrijn Bogman, Jochen Brumm, Carsten Hofmann, Mylène Giraudon, Markus Niggli, Carolina Sturm-Pellanda, Annette Sauter, Stefan Sturm, Bernhard Mangold, Christophe Schmitt
BACKGROUND AND OBJECTIVE: Taspoglutide, a glucagon-like peptide-1 agonist, like native glucagon-like peptide-1, delays gastric emptying time and prolongs intestinal transit time, which may alter the pharmacokinetics of concomitantly administered oral drugs. The effect of taspoglutide on the pharmacokinetics of five oral drugs commonly used in patients with type 2 diabetes mellitus was assessed in healthy subjects. METHODS: Five clinical pharmacology studies evaluated the potential drug-drug interaction between multiple subcutaneous taspoglutide doses and a single dose of lisinopril, warfarin, and simvastatin and multiple doses of digoxin and an oral contraceptive containing ethinylestradiol and levonorgestrel...
April 9, 2019: Clinical Pharmacokinetics
https://read.qxmd.com/read/30945118/effect-of-oral-semaglutide-on-the-pharmacokinetics-of-lisinopril-warfarin-digoxin-and-metformin-in-healthy-subjects
#30
JOURNAL ARTICLE
Tine A Bækdal, Jeanett Borregaard, Cilie W Hansen, Mette Thomsen, Thomas W Anderson
BACKGROUND: Oral semaglutide is a tablet co-formulation of the human glucagon-like peptide-1 (GLP-1) analog semaglutide with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The absorption of coadministered oral drugs may be altered due to enhancement by SNAC, potential gastric emptying delay by semaglutide, or other mechanisms. Two one-sequence crossover trials investigated the effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin...
September 2019: Clinical Pharmacokinetics
https://read.qxmd.com/read/30499733/oral-semaglutide-for-the-treatment-of-type-2-diabetes
#31
REVIEW
Maka S Hedrington, Stephen N Davis
Glucagon-like peptide-1 (GLP-1) receptor agonists are highly potent antihyperglycemic drugs that impose low risk of hypoglycemia and also result in body weight reduction. Currently, all approved members of the class require administration by injection. Areas covered: This manuscript reviews oral semaglutide-an experimental GLP-1 receptor agonist in phase-3 clinical development. Available pharmacological and clinical data of the drug are reviewed, and important end-points described. Expert opinion: Oral peptide delivery has become possible with the discovery of absorption enhancers...
February 2019: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/30427584/evaluation-of-drug-drug-interactions-of-rucaparib-and-cyp1a2-cyp2c9-cyp2c19-cyp3a-and-p-gp-substrates-in-patients-with-an-advanced-solid-tumor
#32
JOURNAL ARTICLE
Jim J Xiao, Dorota Nowak, Rodryg Ramlau, Monika Tomaszewska-Kiecana, Piotr J Wysocki, Jeff Isaacson, Jeri Beltman, Eileen Nash, Robert Kaczanowski, Gerhard Arold, Simon Watkins
This phase 1 study (CO-338-044; NCT02740712), conducted in patients with an advanced solid tumor, evaluated the effect of the poly(ADP-ribose) polymerase inhibitor rucaparib on the pharmacokinetics of caffeine 200 mg, warfarin 10 mg, omeprazole 40 mg, and midazolam 2 mg (cytochrome P450 [CYP] 1A2, CYP2C9, CYP2C19, and CYP3A substrates; dosed as a cocktail) and digoxin 0.25 mg (P-glycoprotein substrate; dosed separately) without rucaparib and following oral rucaparib 600 mg twice daily (BID). Geometric mean (GM) ratios (90% CI) of AUC from time zero to last quantifiable measurement with and without rucaparib were: caffeine, 2...
November 14, 2018: Clinical and Translational Science
https://read.qxmd.com/read/30299591/effectiveness-and-safety-of-rivaroxaban-vs-warfarin-in-patients-with-non-valvular-atrial-fibrillation-and-heart-failure
#33
MULTICENTER STUDY
Brandon K Martinez, Thomas J Bunz, Daniel Eriksson, Anna-Katharina Meinecke, Nitesh A Sood, Craig I Coleman
AIMS: Heart failure (HF) is a common co-morbidity in non-valvular atrial fibrillation (NVAF) patients and a potent risk factor for stroke, bleeding, and a decreased time-in-therapeutic range with warfarin. We assessed the real-world effectiveness and safety of rivaroxaban and warfarin in NVAF patients with co-morbid HF. METHODS AND RESULTS: Using US Truven MarketScan Commercial and Medicare supplemental database claims data from 11/2011 to 12/2016, we identified oral anticoagulant (OAC)-naïve NVAF patients with HF (International Classification of Diseases, 10th Revision codes of I50 or I09...
February 2019: ESC Heart Failure
https://read.qxmd.com/read/30062075/management-of-atrial-fibrillation-in-patients-on-ibrutinib-a-cleveland-clinic-experience
#34
JOURNAL ARTICLE
Sidra Khalid, Samin Yasar, Aariez Khalid, Timothy Pp Spiro, Abdo Haddad, Hamed Daw
Background Ibrutinib is a Bruton's tyrosine kinase inhibitor, which is United States Food and Drug Administration (FDA)-approved for chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia. Ibrutinib is associated with atrial fibrillation and bleeding events. Our aim is to determine the management of prior atrial fibrillation when starting ibrutinib, as well as ibrutinib-induced atrial fibrillation. Our focus is on which rate and rhythm control strategies to use and decisions regarding the use of antiplatelet and anticoagulation agents...
May 29, 2018: Curēus
https://read.qxmd.com/read/29582403/medications-and-prescribing-patterns-as-factors-associated-with-hospitalizations-from-long-term-care-facilities-a-systematic-review
#35
REVIEW
Kate N Wang, J Simon Bell, Esa Y H Chen, Julia F M Gilmartin-Thomas, Jenni Ilomäki
BACKGROUND: Residents of long-term care facilities (LTCFs) are at high risk of hospitalization. Medications are a potentially modifiable risk factor for hospitalizations. OBJECTIVE: Our objective was to systematically review the association between medications or prescribing patterns and hospitalizations from LTCFs. METHODS: We searched MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and International Pharmaceutical Abstracts (IPA) from inception to August 2017 for longitudinal studies reporting associations between medications or prescribing patterns and hospitalizations...
May 2018: Drugs & Aging
https://read.qxmd.com/read/29556685/mortality-among-patients-due-to-adverse-drug-reactions-that-lead-to-hospitalization-a-meta-analysis
#36
JOURNAL ARTICLE
Tejas K Patel, Parvati B Patel
PURPOSE: The aim of this study was to estimate the prevalence of mortality among patients due to adverse drug reactions that lead to hospitalisation (fatal ADRAd ), to explore the heterogeneity in its estimation through subgroup analysis of study characteristics, and to identify system-organ classes involved and causative drugs for fatal ADRAd . METHODS: We identified prospective ADRAd -related studies via screening of the PubMed and Google Scholar databases with appropriate key terms...
June 2018: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/29019431/synthesis-and-spectroscopic-characterization-study-of-new-palladium-complexes-containing-bioactive-o-o-chelated-ligands-evaluation-of-the-dna-protein-bsa-interaction-in-vitro-antitumoral-activity-and-molecular-docking
#37
JOURNAL ARTICLE
Kazem Karami, Zohreh Mehri Lighvan, Hossein Farrokhpour, Maryam Dehdashti Jahromi, Amir Abbas Momtazi-Borojeni
[Pd{(C,N)-C6H4CH2NH(Et) (Qu)] (2) and [Pd{(C,N)-C6H4CH2NH(Et) (Nar)] (3) (Qu=Quercetin, Nar=Naringin) mononuclear palladium (II) complexes have been synthesized and characterized using elemental analysis, IR and electronic spectroscopy. The interaction of the prepared complexes with calf thymus DNA (CT DNA) and bovine serum albumin (BSA), monitored by UV-visible and fluorescence titrations, respectively, have been carried out to better understand the mode of their action under biological conditions. Intercalative binding mode between the complexes and DNA is suggested by the binding constant (Kb) values of 2...
October 11, 2017: Journal of Biomolecular Structure & Dynamics
https://read.qxmd.com/read/28865153/evaluation-of-the-pharmacokinetic-drug-interaction-potential-of-tivantinib-arq-197-using-cocktail-probes-in-patients-with-advanced-solid-tumours
#38
JOURNAL ARTICLE
Masaya Tachibana, Kyriakos P Papadopoulos, John H Strickler, Igor Puzanov, Roohi Gajee, Yibin Wang, Hamim Zahir
AIMS: This phase 1, open-label, crossover study sought to evaluate drug-drug interactions between tivantinib and cytochrome P450 (CYP) substrates and tivantinib and P-glycoprotein. METHODS: The effect of tivantinib doses on the pharmacokinetics of the probe drugs for CYP1A2 (caffeine), CYP2C9 (S-warfarin), CYP2C19 (omeprazole), and CYP3A4 (midazolam), and for P-glycoprotein (digoxin) was investigated in 28 patients with advanced cancer using a cocktail probe approach...
January 2018: British Journal of Clinical Pharmacology
https://read.qxmd.com/read/28808886/assessment-of-pharmacokinetic-interactions-between-obeticholic-acid-and-caffeine-midazolam-warfarin-dextromethorphan-omeprazole-rosuvastatin-and-digoxin-in-phase-1-studies-in-healthy-subjects
#39
JOURNAL ARTICLE
Jeffrey E Edwards, Lise Eliot, Andrew Parkinson, Sharon Karan, Leigh MacConell
INTRODUCTION: Obeticholic acid (OCA), a potent and selective farnesoid X receptor agonist, is indicated for the treatment of primary biliary cholangitis (PBC). We investigated the potential drug-drug interaction effect of OCA on metabolic CYP450 enzymes and drug transporters. METHODS: Five phase 1 single-center, open-label, fixed-sequence, inpatient studies were conducted in healthy adult subjects to evaluate the effect of oral daily doses of 10 or 25 mg OCA on single-dose plasma pharmacokinetics of specific probe substrates for enzymes CYP1A2 (caffeine, R-warfarin), CYP3A (midazolam, R-warfarin), CYP2C9 (S-warfarin), CYP2D6 (dextromethorphan), CYP2C19 (omeprazole), and drug transporters, BCRP/OATP1B1/OATP1B3 (rosuvastatin), and P-gp (digoxin)...
September 2017: Advances in Therapy
https://read.qxmd.com/read/28701029/high-risk-prescribing-in-an-irish-primary-care-population-trends-and-variation
#40
JOURNAL ARTICLE
Catherine J Byrne, Caitriona Cahir, Carmel Curran, Kathleen Bennett
AIMS: The aims of the present study were to examine the prevalence of high-risk prescribing (HRP) in community-dwelling adults in Ireland from 2011-2015 using consensus-validated indicators, factors associated with HRP, and the variation in HRP between general practitioners (GPs) and in the dispensing of high-risk prescriptions between pharmacies. METHODS: A repeated cross-sectional national pharmacy claims database study was conducted. Prescribing indicators were based on those developed in formal consensus studies and applicable to pharmacy claims data...
December 2017: British Journal of Clinical Pharmacology
keyword
keyword
115073
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.